Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

ClinicalTrials.gov ID: NCT00703326

Public ClinicalTrials.gov record NCT00703326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer

Study identification

NCT ID
NCT00703326
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
1,144 participants

Conditions and interventions

Conditions

Interventions

  • Placebo Other
  • docetaxel Drug
  • ramucirumab (IMC-1121B) Biological

Other · Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 5, 2008
Primary completion
Mar 30, 2013
Completion
Nov 18, 2020
Last update posted
Dec 5, 2021

2008 – 2020

United States locations

U.S. sites
65
U.S. states
24
U.S. cities
55
Facility City State ZIP Site status
ImClone Investigational Site Birmingham Alabama 35202
ImClone Investigational Site Mobile Alabama 36608
ImClone Investigational Site Chandler Arizona 85224
ImClone Investigational Site Gilbert Arizona 85297
ImClone Investigational Site Mesa Arizona 85206
ImClone Investigational Site Alhambra California 91801
ImClone Investigational Site Bakersfield California 93309
ImClone Investigational Site Chula Vista California 91911
ImClone Investigational Site La Mesa California 91942
ImClone Investigational Site Los Angeles California 90095
ImClone Investigational Site Oceanside California 92056
ImClone Investigational Site Pasadena California 01107
ImClone Investigational Site Pasadena California 91105
ImClone Investigational Site San Diego California 92123
ImClone Investigational Site Santa Barbara California 93105
ImClone Investigational Site Santa Maria California 93454
ImClone Investigational Site Santa Monica California 90404
ImClone Investigational Site Solvang California 93463
ImClone Investigational Site Valencia California 91355
ImClone Investigational Site Aurora Colorado 80045
ImClone Investigational Site Fort Lauderdale Florida 33308
ImClone Investigational Site Gainesville Florida 32605
ImClone Investigational Site New Port Richey Florida 34655
ImClone Investigational Site Atlanta Georgia 30341
ImClone Investigational Site Atlanta Georgia 30342
ImClone Investigational Site Macon Georgia 31217
ImClone Investigational Site Marietta Georgia 30060
ImClone Investigational Site Alton Illinois 62002
ImClone Investigational Site Chicago Illinois 60076
ImClone Investigational Site Chicago Illinois 60611
ImClone Investigational Site Skokie Illinois 60076
ImClone Investigational Site Elkhart Indiana 46514
ImClone Investigational Site Mishawaka Indiana 46545
ImClone Investigational Site South Bend Indiana 46601
ImClone Investigational Site Westville Indiana 46891
ImClone Investigational Site Lexington Kentucky 40604
ImClone Investigational Site Lansing Michigan 48912
ImClone Investigational Site Saint Joseph Michigan 49085
ImClone Investigational Site Minneapolis Minnesota 55415
ImClone Investigational Site Southaven Mississippi 38671
ImClone Investigational Site St Louis Missouri 63136
ImClone Investigational Site Grand Island Nebraska 68803
ImClone Investigational Site Kearney Nebraska 68845
ImClone Investigational Site Henderson Nevada 89052
ImClone Investigational Site New York New York 10011
ImClone Investigational Site Charlotte North Carolina 15830
ImClone Investigational Site Charlotte North Carolina 28203
ImClone Investigational Site Charlotte North Carolina 28210
ImClone Investigational Site Charlotte North Carolina 28211
ImClone Investigational Site Charlotte North Carolina 28262
ImClone Investigational Site Charlotte North Carolina 28294
ImClone Investigational Site Bismarck North Dakota 58501
ImClone Investigational Site Oklahoma City Oklahoma 73120
ImClone Investigational Site Portland Oregon 97239
ImClone Investigational Site West Reading Pennsylvania 19611
ImClone Investigational Site Bartlett Tennessee 38133
ImClone Investigational Site Germantown Tennessee 38138
ImClone Investigational Site Memphis Tennessee 38104
ImClone Investigational Site Memphis Tennessee 38119
ImClone Investigational Site Memphis Tennessee 38120
ImClone Investigational Site Niles Tennessee 49120
ImClone Investigational Site Oxford Tennessee 38655
ImClone Investigational Site Lubbock Texas 79410
ImClone Investigational Site Temple Texas 76508
ImClone Investigational Site Salt Lake City Utah 84106

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 167 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00703326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 5, 2021 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00703326 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →